The Emerging Profile of Cross-Resistance among the Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors

Por Sluis-Cremer, Nicolas
Publicado em 2014

Radiation Target Analyses of DNA Template/Primer Complexes

Por Sluis-Cremer, Nicolas, Kempner, Ellis S.
Publicado em 2006

Stereo-selectivity of HIV-1 reverse transcriptase toward isomers of thymidine-5′-O-1-thiotriphosphate

Por Radzio, Jessica, Sluis-Cremer, Nicolas
Publicado em 2005

Mechanisms of inhibition of HIV replication by nonnucleoside reverse transcriptase inhibitors

Por Sluis-Cremer, Nicolas, Tachedjian, Gilda
Publicado em 2008

Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase

Por Radzio, Jessica, Sluis-Cremer, Nicolas
Publicado em 2011

In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of...

Por Giacobbi, Nicholas S., Sluis-Cremer, Nicolas
Publicado no Antimicrob Agents Chemother (2017)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

Por Schauer, Grant, Leuba, Sanford, Sluis-Cremer, Nicolas
Publicado em 2013

Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding

Por Sluis-Cremer, Nicolas, Temiz, N. Alpay, Bahar, Ivet
Publicado em 2004

Structure–activity relationships in HIV-1 reverse transcriptase revealed by radiation target analysis

Por Sluis-Cremer, Nicolas, Kempner, Ellis, Parniak, Michael A.
Publicado em 2003

Novel high throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of action

Por Sheen, Chih-Wei, Alptürk, Onur, Sluis-Cremer, Nicolas
Publicado no Biochem J (2014)

Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4(+) T Cells following Latency Reversal

Por Zerbato, Jennifer M., Tachedjian, Gilda, Sluis-Cremer, Nicolas
Publicado no Antimicrob Agents Chemother (2017)

Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses

Por Xia, Qing, Radzio, Jessica, Anderson, Karen S., Sluis-Cremer, Nicolas
Publicado em 2007

Mechanism by which a Glutamine to Leucine Substitution at Residue 509 in the Ribonuclease H Domain of HIV-1 Reverse Transcriptase Confers Zidovudine Resistance

Por Brehm, Jessica H., Mellors, John W., Sluis-Cremer, Nicolas
Publicado em 2008

Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection

Por Sluis-Cremer, Nicolas, Wainberg, Mark A., Schinazi, Raymond F.
Publicado no Future Microbiol (2015)

N348I in Reverse Transcriptase Provides a Genetic Pathway for HIV-1 to Select TAMs and Mutations Antagonistic to TAMs

Por Radzio, Jessica, Yap, Soo-Huey, Tachedjian, Gilda, Sluis-Cremer, Nicolas
Publicado em 2010

N348I in HIV-1 Reverse Transcriptase Decreases Susceptibility to Tenofovir and Etravirine in Combination with Other Resistance Mutations

Por Sluis-Cremer, Nicolas, Moore, Katie, Radzio, Jessica, Sonza, Secondo, Tachedjian, Gilda
Publicado em 2010

The Acyclic 2,4-Diaminopyrimidine Nucleoside Phosphonate Acts as a Purine Mimetic in HIV-1 Reverse Transcriptase DNA Polymerization

Por Herman, Brian D., Votruba, Ivan, Holý, Antonin, Sluis-Cremer, Nicolas, Balzarini, Jan
Publicado em 2010

Molecular mechanism of HIV-1 resistance to 3’-azido-2’,3’-dideoxyguanosine

Por Meteer, Jeffrey D., Schinazi, Raymond F., Mellors, John W., Sluis-Cremer, Nicolas
Publicado em 2013

In Vitro Characterization of a Sustained-Release Formulation for Enfuvirtide

Por Rothstein, Sam N., Huber, Kelly D., Sluis-Cremer, Nicolas, Little, Steven R.
Publicado em 2014

Competitive Fitness Assays Indicate that the E138A Substitution in HIV-1 Reverse Transcriptase Decreases In Vitro Susceptibility to Emtricitabine

Por Sluis-Cremer, Nicolas, Huber, Kelly D., Brumme, Chanson J., Harrigan, P. Richard
Publicado em 2014